Mimedx GROUP, Inc. (MDXG) intrinsic value & 10-year financials

Mimedx GROUP, Inc. (MDXG) has a Graham intrinsic value of $9.30 per share. At $4.43 on Oct 17, 2026, the stock trades 52% below that value. Over the last 10 fiscal years revenue grew 7.3% a year to $418.6M, with an average return on invested capital of 75.7%.

Graham intrinsic value
$9.30
Share price (Oct 17, 2026)
$4.43
Price vs Graham value
52% below
Market cap
$663.3M
Revenue (FY2025)
$418.6M
Revenue growth (10-yr CAGR)
7.3%
ROIC (10-yr avg)
75.7%
Free cash flow (FY2025)
—

MDXG 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $418.6M $48.6M $0.32 — 15.3% 41.8%
FY2024 $348.9M $42.4M $0.28 — 16.9% 38.8%
FY2023 $321.5M $58.2M $0.37 $24.8M 11.5% 95.4%
FY2022 $267.8M -$30.2M -$0.33 -$19.4M -9.3% 73.6%
FY2021 $258.6M -$10.3M -$0.15 -$5.2M -1.9% 12.5%
FY2020 $248.2M -$49.3M -$0.77 — -18.3% 637.8%
FY2019 $299.3M -$25.6M -$0.24 — -7.1% -110.1%
FY2018 $359.1M -$30.0M -$0.28 — -1.1% -86.5%
FY2017 $321.1M $64.7M $0.56 — 14.4% 44.7%
FY2016 $221.7M $12.0M $0.11 — 8.3% 9.2%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

MIMEDX GROUP, INC. has demonstrated mature, steady growth, with revenue compounding at 7.3% annually over the past decade.

MIMEDX GROUP, INC. returns on capital have been average, hovering around 12.6% ROIC over the decade.

MIMEDX GROUP, INC. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, MIMEDX GROUP, INC. is modeled at 12.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $9.30 per share.

MDXG stock: frequently asked questions

What is the intrinsic value of Mimedx GROUP, Inc. (MDXG) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 12.6% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, MDXG's intrinsic value is about $9.30 per share.

Is MDXG stock undervalued?

At $4.43 (close on Oct 17, 2026), MDXG trades 52% below its Graham value of $9.30. On Graham's terms that leaves a margin of safety. A formula is a starting point for research, not a recommendation.

How fast has Mimedx GROUP, Inc. grown?

Revenue went from $221.7M in fiscal 2016 to $418.6M in fiscal 2025, a compound annual growth rate of 7.3%. Net income was $48.6M in fiscal 2025.

What is MDXG's return on invested capital?

Average ROIC over the last 10 fiscal years was 75.7%, and average return on equity was 3040.2%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this MDXG data come from?

From Mimedx GROUP, Inc.'s annual 10-K filings on SEC EDGAR. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar surgical & medical instruments & apparatus stocks